Kalytera Therapeutics Completes Acquisition of Talent Biotechs

Submit the press release

Lead program in Graft versus Host Disease (“GvHD”), a life-threatening condition that can occur following stem cell or bone marrow transplantation
Four Phase 2 clinical studies evaluating CBD in the prevention and treatment of GvHDOrphan drug designations (“ODD”) granted in the U.S. and EuropeAdvancing towards FDA Phase 2b clinical studiesVANCOUVER, British Columbia, Feb. 16, 2017 — Kalytera Therapeutics, Inc. (TSX-V:KALY) (“Kalytera”) announced today that it has successfully completed the previously announced acquisition (the “Acquisition”) of Talent Biotechs Ltd. (“Talent”), strengthening Kalytera’s position as an emerging market leader in cannabidiol (“CBD”) pharmaceuticals. Talent is a privately held, Israeli-based company evaluating the use of CBD to prevent and treat Graft versus Host Disease (“GvHD”).“We feel incredibly fortunate to be continuing Talent’s groundbreaking work in GvHD,” said Andrew Salzman, M.D., Kalytera’s Chief Executive Officer. “There are currently few options

... read more at: http://www.satprnews.com/2017/02/16/kalytera-therapeutics-completes-acquisition-of-talent-biotechs/